E. Tzamakou

Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group

Evangelos Briasoulis, Ian Judson, Nicholas Pavlidis et al. · Journal of Clinical Oncology · 2000 · 60 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration

Evangelos Briasoulis, Vasilios Karavasilis, D. Anastasopoulos et al. · Annals of Oncology · 1999 · 51 citations

Pharmacy, Oncology, Pharmacology +17

Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel

Evangelos Briasoulis, Vasilios Karavasilis, E. Tzamakou et al. · Cancer Chemotherapy and Pharmacology · 2004 · 47 citations

Pharmacy, Pharmacokinetics, Pharmacology +14

Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study

Evangelos Briasoulis, Vasilios Karavasilis, E. Tzamakou et al. · Anti-Cancer Drugs · 2002 · 20 citations

Medicine, Oncology, Pharmacology +17

Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx™) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors

Evangelos Briasoulis, George Pentheroudakis, Vasilios Karavasilis et al. · Annals of Oncology · 2004 · 17 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17